Company / Net Income
BioMarin Pharmaceutical Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$348.9M
FY2025
5-year range
-$64.1M / $426.9M
FY2021-FY2025
Trend
-18.3%
vs FY2024
Sector context
#26 of 216
Health Care
What the data says
BioMarin Pharmaceutical's net income of $349M is higher than 88% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$630M in FY2016 to $854M in FY2020.
Based on SEC 10-K filings.
$349M in FY2025 with a 5-year CAGR of -16.4%. Top quartile in the Health Care sector.
Improved from $168M to $349M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +35.1%
- 5-Year CAGR
- -16.4%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 216This company $348.9M Sector average $454.3M
▼
-23.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -16.4%, indicating a declining trend.
- In FY2025, net income decreased 18.3% year-over-year.
- Ranks #26 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $348.9M | -18.3% |
| FY2024 | $426.9M | +154.6% |
| FY2023 | $167.6M | +18.4% |
| FY2022 | $141.6M | +320.9% |
| FY2021 | -$64.1M | -107.5% |
| FY2020 | $854.0M | +3681.1% |
| FY2019 | -$23.8M | +69.1% |
| FY2018 | -$77.2M | +34.0% |
| FY2017 | -$117.0M | +81.4% |
| FY2016 | -$630.2M | -266.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026